KoBioLabs, Inc. Logo

KoBioLabs, Inc.

Develops AI-driven microbiome therapeutics for immune, metabolic, and brain disorders.

348150 | KO

Overview

Corporate Details

ISIN(s):
KR7348150004
LEI:
Country:
South Korea
Address:
서울특별시 관악구 관악로 1 220동 745-1호(신림동, 서울대학교종합연구동), 서울특별시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

KoBioLabs, Inc. is a biotechnology company specializing in the development of innovative microbiome therapeutics. The company utilizes its proprietary Smartiome® platform, an AI-driven, multi-omics drug discovery engine using a reverse-translation approach, to identify novel candidates for its pipelines. Its research and development efforts are primarily focused on creating treatments for a range of immune, metabolic, and brain disorders. KoBioLabs employs advanced technologies such as microbe-based drug delivery systems (mDDS) and biofoundry techniques to create a new class of drugs, aiming to address unmet medical needs by modulating biological pathways through microbial interactions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.5 MB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.1 MB
2025-03-31 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 28.2 KB
2025-03-31 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 11.3 KB
2025-03-31 00:00
Board/Management Information
[기재정정]사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 14.1 KB
2025-03-20 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 483.3 KB
2025-03-20 00:00
Audit Report / Information
감사보고서제출
Korean 26.0 KB
2025-03-14 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 225.0 KB
2025-03-06 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 17.6 KB
2025-02-14 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.2 KB
2024-12-13 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.3 KB
2024-11-14 00:00
Annual Report
[기재정정]사업보고서 (2023.12)
Korean 1.8 MB
2024-11-14 00:00
Quarterly Report
[기재정정]분기보고서 (2024.03)
Korean 1.1 MB
2024-11-14 00:00
Interim Report
[기재정정]반기보고서 (2024.06)
Korean 1.5 MB
2024-11-14 00:00
Quarterly Report
분기보고서 (2024.09)
Korean 1.2 MB

Automate Your Workflow. Get a real-time feed of all KoBioLabs, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KoBioLabs, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KoBioLabs, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

VALIRX PLC Logo
Advancing oncology & women's health therapeutics and offering preclinical research services.
United Kingdom
VAL
VALUE GOLF Inc. Logo
A golf services hub offering reservations, solo player bookings, e-commerce, lessons, and tours.
Japan
3931
Value HR Co., Ltd. Logo
Offers a health management platform and consulting for corporate health insurance societies in Japan.
Japan
6078
Global OTA for curated tours & experiences, focusing on travel to and from Japan.
Japan
7048
A South Korean travel company offering global tour packages, flights, hotels, and corporate travel.
South Korea
094850
Virax Biolabs Group Ltd Logo
Specializes in T-cell immunity tests and diagnostics for profiling viral disease responses.
United States of America
VRAX
VisionSys AI Inc Logo
Develops AI-powered brain-computer interfaces for the healthcare and biotech sectors.
United States of America
VSA
Vivesto Logo
Develops and licenses novel cancer therapies for humans and animals using proprietary drug delivery.
Sweden
VIVE
Vor Biopharma Inc. Logo
Clinical-stage biotech developing next-gen medicines that target the root cause of autoimmune disease.
United States of America
VOR
Voronoi, Inc. Logo
Develops selective kinase inhibitors and targeted protein degraders for precision oncology.
South Korea
310210

Talk to a Data Expert

Have a question? We'll get back to you promptly.